Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
Abstract Background Treatment with onabotulinumtoxin A (BT-A) is safe and effective for chronic migraine (CM). Several studies assessed possible predictors of response to treatment with BT-A, but there is little knowledge on the frequency and predictors of sustained response. The aim of this study w...
Main Authors: | Raffaele Ornello, Simona Guerzoni, Carlo Baraldi, Luana Evangelista, Ilaria Frattale, Carmine Marini, Cindy Tiseo, Francesca Pistoia, Simona Sacco |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s10194-020-01113-6 |
Similar Items
-
Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA
by: Enrique Martínez-Pías, et al.
Published: (2021-06-01) -
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
by: Stephen D. Silberstein, et al.
Published: (2020-10-01) -
OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
by: Jason C. Ray, et al.
Published: (2021-06-01) -
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
by: Raffaele Ornello, et al.
Published: (2019-10-01) -
Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins
by: Sara M. Schaefer, et al.
Published: (2015-07-01)